<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>personalized oncology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/personalized-oncology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 21:18:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>personalized oncology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Sex-Specific Molecular Insights into Bladder Cancer Revealed</title>
		<link>https://bioengineer.org/sex-specific-molecular-insights-into-bladder-cancer-revealed/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 21:17:44 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[İşte 5 uygun etiket (sadece virgülle ayrılmış): **Sex-specific bladder cancer]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **Bladder cancer]]></category>
		<category><![CDATA[microRNA]]></category>
		<category><![CDATA[microRNA biomarkers]]></category>
		<category><![CDATA[Molecular sex differences** **Kısa Açıklama:** 1. **Sex-specific bladder cancer:** Çalışmanın temel odağı olan mesane kanserindeki cinsiyete bağlı farklılıkları doğrudan]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[sex differences]]></category>
		<category><![CDATA[Transcriptome analysis]]></category>
		<category><![CDATA[Transcriptome profiling]]></category>
		<guid isPermaLink="false">https://bioengineer.org/sex-specific-molecular-insights-into-bladder-cancer-revealed/</guid>

					<description><![CDATA[In a groundbreaking study published in Biology of Sex Differences, researchers led by Wang, Y., along with collaborators Bhandary, P., and Moore, J.H., have unveiled critical insights into the molecular mechanisms underlying bladder cancer, particularly focusing on sex-specific variations in the disease’s expression and progression. The integrative analysis harnesses both microRNA and transcriptome profiling techniques, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319999</post-id>	</item>
		<item>
		<title>Unraveling Small-Cell Lung Cancer: A Multi-Omic Approach</title>
		<link>https://bioengineer.org/unraveling-small-cell-lung-cancer-a-multi-omic-approach/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 04:10:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[biomarker discovery]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[multi-omic profiling]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[small-cell lung cancer]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-small-cell-lung-cancer-a-multi-omic-approach/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have conducted a comprehensive multi-omic profiling of small-cell lung cancer (SCLC), revealing crucial insights into its heterogeneity, microenvironment, and biomarker landscape. This innovative approach combines genomic, transcriptomic, proteomic, and metabolomic analyses, providing a holistic understanding of one of the most aggressive forms of lung cancer. The findings not only shed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319634</post-id>	</item>
		<item>
		<title>Revolutionizing Pancreatic Cancer: Immunology and Therapy Breakthroughs</title>
		<link>https://bioengineer.org/revolutionizing-pancreatic-cancer-immunology-and-therapy-breakthroughs/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 19:08:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Combination cancer therapies]]></category>
		<category><![CDATA[İçeriğe göre en uygun 5 Türkçe etiket: **Pankreas kanseri]]></category>
		<category><![CDATA[immünoterapi]]></category>
		<category><![CDATA[Kişiselleştirilmiş Tıp]]></category>
		<category><![CDATA[Neoantigen immunotherapy]]></category>
		<category><![CDATA[Pancreatic cancer immunology]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[Tedavi direnci** * **Pankreas kanseri:** Makalenin ana konusu. * **İmmünoterapi:** İçerikte vurgulanan yeni tedavi]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tümör mikroçevresi]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-pancreatic-cancer-immunology-and-therapy-breakthroughs/</guid>

					<description><![CDATA[Pancreatic cancer remains one of the most aggressive malignancies globally, with a historically poor prognosis and limited therapeutic options. Recent advancements in the understanding of its immunological landscape, combined with translational research efforts, are paving the way for new paradigms in treatment strategies. A significant work that stands out in this area is authored by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318023</post-id>	</item>
		<item>
		<title>Actinomyces Predicts Immune Therapy Success in Lung Cancer</title>
		<link>https://bioengineer.org/actinomyces-predicts-immune-therapy-success-in-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 17 Jan 2026 10:22:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Actinomyces]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[Salivary Microbiome]]></category>
		<guid isPermaLink="false">https://bioengineer.org/actinomyces-predicts-immune-therapy-success-in-lung-cancer/</guid>

					<description><![CDATA[In a groundbreaking study soon to be published, researchers have unveiled a vital connection between salivary microbial signatures and the effectiveness of immune-checkpoint inhibitor monotherapy in patients diagnosed with advanced non–small cell lung cancer (NSCLC). This innovative research, led by a team of experts including Cavaliere, Fogolari, and Iuliani, explores the intricate world of microbes [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317741</post-id>	</item>
		<item>
		<title>Plasma Gelsolin, MRI Radiomics: Predicting Platinum Resistance</title>
		<link>https://bioengineer.org/plasma-gelsolin-mri-radiomics-predicting-platinum-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 01 Dec 2025 23:38:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Epithelial ovarian cancer]]></category>
		<category><![CDATA[MRI radiomics]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[Plasma gelsolin biomarker]]></category>
		<category><![CDATA[Platinum resistance prediction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/plasma-gelsolin-mri-radiomics-predicting-platinum-resistance/</guid>

					<description><![CDATA[In the realm of oncology, understanding the intricate mechanisms of drug resistance is pivotal for enhancing treatment efficacy. A groundbreaking study spearheaded by Gerber and colleagues sheds light on the intersection of circulating plasma gelsolin levels and MRI-based radiomics in predicting platinum resistance in epithelial ovarian cancer—one of the most challenging malignancies faced by women [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">304199</post-id>	</item>
		<item>
		<title>Immunotherapy Plus Radiotherapy in Advanced Lung Cancer</title>
		<link>https://bioengineer.org/immunotherapy-plus-radiotherapy-in-advanced-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 30 Oct 2025 22:39:38 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[bone metastasis treatment]]></category>
		<category><![CDATA[immunotherapy-radiotherapy combination]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[stage IV NSCLC]]></category>
		<category><![CDATA[synergistic cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/immunotherapy-plus-radiotherapy-in-advanced-lung-cancer/</guid>

					<description><![CDATA[Recent advancements in oncological therapies have revealed significant implications for the management of stage IV non-small cell lung carcinoma (NSCLC) patients, particularly those with bone metastases. A groundbreaking study conducted by Beyon et al. delves into the effectiveness of immunotherapy in conjunction with radiotherapy, a combination that may redefine treatment protocols in advanced cancer care. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">289329</post-id>	</item>
		<item>
		<title>Scientists Create a Minimally Invasive, More Accurate Technique to Evaluate Immunotherapy Success</title>
		<link>https://bioengineer.org/scientists-create-a-minimally-invasive-more-accurate-technique-to-evaluate-immunotherapy-success/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 20:23:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immune checkpoint blockade]]></category>
		<category><![CDATA[immunotherapy prediction]]></category>
		<category><![CDATA[immunotherapy success prediction]]></category>
		<category><![CDATA[liquid biopsy technique]]></category>
		<category><![CDATA[minimally invasive monitoring]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[predictive biomarkers]]></category>
		<guid isPermaLink="false">https://bioengineer.org/scientists-create-a-minimally-invasive-more-accurate-technique-to-evaluate-immunotherapy-success/</guid>

					<description><![CDATA[Immunotherapy has revolutionized the landscape of cancer treatment, transforming previously incurable malignancies into potentially manageable diseases by harnessing the patient’s immune system. Despite its monumental promise, a persistent challenge remains: the unpredictable and inconsistent response rates among patients. Addressing this critical issue, researchers at the Cancer Center at Illinois, in collaboration with experts at the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285404</post-id>	</item>
		<item>
		<title>Cell-Free DNA Reflects Tumor Transcription Factor Activity</title>
		<link>https://bioengineer.org/cell-free-dna-reflects-tumor-transcription-factor-activity/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 08 Oct 2025 08:10:34 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[cancer genomics]]></category>
		<category><![CDATA[cancer genomics innovations]]></category>
		<category><![CDATA[cell-free DNA]]></category>
		<category><![CDATA[cfDNA methylation analysis]]></category>
		<category><![CDATA[non-invasive biomarkers]]></category>
		<category><![CDATA[non-invasive cancer biomarkers]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[transcription factor activity profiling]]></category>
		<category><![CDATA[transcription factors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cell-free-dna-reflects-tumor-transcription-factor-activity/</guid>

					<description><![CDATA[In a groundbreaking study, Tamaki et al. have unveiled a novel method utilizing cell-free DNA (cfDNA) to explore the activities of over 370 transcription factors in tumors. This innovative approach promises to revolutionize our understanding of tumor biology and may provide unprecedented insights into cancer genomics. The research is set to be published in BMC [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">277421</post-id>	</item>
		<item>
		<title>Groundbreaking Genomic Test Forecasts Hormone Therapy Benefits in Recurrent Prostate Cancer Treatment</title>
		<link>https://bioengineer.org/groundbreaking-genomic-test-forecasts-hormone-therapy-benefits-in-recurrent-prostate-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 28 Sep 2025 20:18:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[BALANCE trial]]></category>
		<category><![CDATA[genomic biomarker]]></category>
		<category><![CDATA[hormone therapy response]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/groundbreaking-genomic-test-forecasts-hormone-therapy-benefits-in-recurrent-prostate-cancer-treatment/</guid>

					<description><![CDATA[A groundbreaking clinical study has unveiled a transformative biomarker that could revolutionize treatment strategies for recurrent prostate cancer patients post-surgery. This pivotal randomized trial reveals that a genomic tumor profiling test can precisely predict which patients stand to gain from adjunct hormone therapy following radiation, establishing the first predictive biomarker in the post-prostatectomy landscape. The [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">272999</post-id>	</item>
		<item>
		<title>Radiomics Predicts Lenvatinib Success in Liver Cancer</title>
		<link>https://bioengineer.org/radiomics-predicts-lenvatinib-success-in-liver-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Sep 2025 01:51:11 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[hepatocellular carcinoma treatment]]></category>
		<category><![CDATA[lenvatinib]]></category>
		<category><![CDATA[lenvatinib efficacy prediction]]></category>
		<category><![CDATA[machine learning in cancer]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[MRI-based radiomics]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[radiomics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/radiomics-predicts-lenvatinib-success-in-liver-cancer/</guid>

					<description><![CDATA[In the realm of oncology, the quest for precision medicine has led to intriguing advancements that hold promise for cancer patients worldwide. A recent study delves into a pivotal area of hepatocellular carcinoma (HCC) treatment, leveraging cutting-edge technology to predict the response to the targeted therapy drug, lenvatinib. This innovative approach utilizes MRI-based radiomics signatures, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268594</post-id>	</item>
		<item>
		<title>Unraveling BRCA2’s Complex Transcriptional Landscape with Hybrid-seq</title>
		<link>https://bioengineer.org/unraveling-brca2s-complex-transcriptional-landscape-with-hybrid-seq/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 27 Aug 2025 17:39:43 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[alternative splicing in cancer]]></category>
		<category><![CDATA[BRCA2 transcriptional landscape]]></category>
		<category><![CDATA[DNA repair mechanisms]]></category>
		<category><![CDATA[Hybrid-seq technology]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-brca2s-complex-transcriptional-landscape-with-hybrid-seq/</guid>

					<description><![CDATA[In the realm of genetics, few topics command as much attention as the BRCA2 gene and its implications in familial breast and ovarian cancers. This gene, a crucial player in DNA repair mechanisms, has long been under the spotlight of genetic research, yet its intricate transcriptional complexity remains partially understood. In a groundbreaking study, Adamopoulos, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">258655</post-id>	</item>
		<item>
		<title>Rice University-Led Team Explores Mitochondrial Targets for Innovative Leukemia Treatments</title>
		<link>https://bioengineer.org/rice-university-led-team-explores-mitochondrial-targets-for-innovative-leukemia-treatments/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 04 Jun 2025 21:38:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[acute myeloid leukemia treatment]]></category>
		<category><![CDATA[cancer metabolism]]></category>
		<category><![CDATA[mitochondrial targeting in cancer]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[translational cancer research]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rice-university-led-team-explores-mitochondrial-targets-for-innovative-leukemia-treatments/</guid>

					<description><![CDATA[Acute myeloid leukemia (AML) represents one of the most formidable challenges in contemporary oncology due to its aggressive nature and remarkable resistance to existing therapies. Traditional treatment modalities such as high-dose chemotherapy and allogeneic bone marrow transplantation have prolonged survival for some patients, yet the overall prognosis remains poor, primarily because of the high rate [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">248381</post-id>	</item>
		<item>
		<title>Mapping the Immune Landscape of Tongue Cancer: A New Frontier in Oncology</title>
		<link>https://bioengineer.org/mapping-the-immune-landscape-of-tongue-cancer-a-new-frontier-in-oncology/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 27 May 2025 17:34:34 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[immune microenvironment]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[spatial tissue imaging]]></category>
		<category><![CDATA[tongue squamous cell carcinoma]]></category>
		<guid isPermaLink="false">https://bioengineer.org/mapping-the-immune-landscape-of-tongue-cancer-a-new-frontier-in-oncology/</guid>

					<description><![CDATA[In the rapidly evolving field of cancer therapy, immunotherapy has emerged as a revolutionary approach, harnessing the innate power of the immune system to target and eliminate malignant cells. Despite its profound success stories in certain cancers like melanoma and lung carcinoma, this mode of treatment has yet to achieve equivalent breakthroughs in all tumor [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246901</post-id>	</item>
	</channel>
</rss>
